Clinical trials: Anti Phospholipid Syndrome
Antiphospholipid Syndrome
Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients With Antiphospholipid Syndrome.
Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy.
- Trial name
- NCT03384485
- Testing
- antiphospholipid syndrome
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Meir Medical Center
Anti-phospholipid Antibobodies in Patients of SLE Presenting With Thrombosis or Pregnancy Complications
Antiphospholipid Antibodies in Patients of Antiphospholipid Syndrome (APS) With Systemic Lupus Erythematosus (SLE).
Evaluation of antiphospholipid antibodies (aPL) profile in Systemic lupus erythematosus (SLE) patients with obstetric and thrombotic complications.
- Trial name
- NCT04963881
- Testing
- Antibody testing
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Fatima Memorial Hospital
Anti-Phospholipids Syndrome (APS), Systemic Lupus Erythematosus (SLE)
Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)
The purpose of that register is to collect medical information about patients suffering of APS with or without associated SLE.
- Trial name
- SAPL-LUPUS (NCT02782039)
- Where
- 2 sites in France
- Volunteers
- 868 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
Longitudinal prospective multicenter Armenian registry of systemic autoimmune, autoinflammatory diseases with constitution of bio-banking.
- Conditions
- Behcet Disease, Antineutrophil Cytoplasmic Antibody (ANCA) Positive Vasculitis, Takayasu Arteritis, Giant Cell Arteritis
- Trial name
- NAREG (NCT05904301)
- Testing
- Usual medical management of patients, additional blood and stool samples for biobanking
- Where
- 6 sites in Armenia
- Volunteers
- 800 people
- Sponsor
- Santé Arménie French-Armenian Research Center
Antiphospholipid Syndrome
Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)
Stroke represents a major cause of morbidity and mortality despite significant progress in recent decades. In individuals under the age of 65, the etiologies of ischemic stroke (IS) are diverse, and management is…
- Trial name
- SAPLAGE (NCT07163338)
- Testing
- Collectio nof blood
- Where
- France
- Volunteers
- 400 people
- Sponsor
- CHU de Reims
Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose…
- Conditions
- Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
- Trial name
- NCT06371417
- Testing
- RAY121
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 144 people
- Sponsor
- Chugai Pharmaceutical
Rheumatic Diseases, Adult Onset Still Disease
Rheumatology Patient Registry and Biorepository
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
- Conditions
- Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT04402086
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Yale University
Antiphospholipid Syndrome, COVID-19 Infection
Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination
Prospective observational study to evaluate a possible change in APS antibody profiles after COVID-19 infection or vaccination
- Conditions
- Antiphospholipid Syndrome, COVID-19 Infection, COVID-19 Vaccination
- Trial name
- APSantiCo (NCT05313048)
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Atrial Fibrillation, Deep Vein Thrombosis
Pharmacogenetics of Warfarin in Puerto Ricans.
Warfarin (Coumadin) is a prescribed "blood thinner" medication used to make the blood less thick in people with high risk of forming blood clots.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Antiphospholipid Syndrome
- Trial name
- NCT01318057
- Where
- Puerto Rico
- Volunteers
- 350 people
- Sponsor
- University of Puerto Rico
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
ANTIPHOSPHOLIPID SYNDROME
Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome
Antiphospholipid syndrome is disease believed to be due to immune cells, cells which normally protect the body, but are now producing the protein which leads to abnormal clotting in the body.
- Trial name
- NCT00278616
- Testing
- Stem Cell Transplantation
- Where
- United States
- Sponsor
- Richard Burt, MD
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
This is an investigator-initiated trial to evaluate the safety and efficacy of anti- CD19-CAR-T cells in the relapse or refractory autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT06420154
- Testing
- anti-CD19-CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Autoimmune diseases refer to a common category of diseases caused by the immune system reacting to self-antigens, leading to tissue damage.
- Conditions
- Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome, ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06828042
- Testing
- anti-CD19 CAR T cell therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital
Antiphospholipid Syndrome
Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
The purpose of this study is to gather information about causes and treatment of Antiphospholipid Syndrome.
- Trial name
- APS (NCT00616317)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, Davis
Antiphospholipid Syndrome in Pregnancy, Anticoagulants
HYDROxychloroquine in Syndrome Primary AntiPhospholipid
Antiphospholipid syndrome (APS) is defined by thrombosis or obstetric complication (≥ 3 spontaneous miscarriages or fetal death or prematurity <34 weeks gestation-related amenorrhea (SA)) associated with antiphospholipid…
- Trial name
- HYDROSAPL (NCT04275778)
- Testing
- Plaquenil 200Mg Tablet
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anti Phospholipid Syndrome
Telitacicept in Primary APS Patients
This is a single-arm pilot study in Peking Union Medical College Hospital. Telitacicept will be added on traditional antithrombotic and immunosuppressive treatment in primary antiphospholipid syndrome (APS) patients with three…
- Trial name
- NCT05078710
- Testing
- Telitacicept
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Antiphospholipid Syndrome, Venous Thromboembolism
Effectivity and Safety of Different Anticoagulants in Patients With Thromboembolic Antiphospholipid Syndrome
Retrospective monocentric registry to evaluate the efficacy and safety of different anticoagulants in patients with thromboembolic antiphospholipid syndrome
- Conditions
- Antiphospholipid Syndrome, Venous Thromboembolism, Arterial Thromboembolism, Major Bleed
- Trial name
- NCT05195372
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT06373081
- Testing
- Anti-CD19-CD3E-CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai Changzheng Hospital
Antiphospholipid Antibody Syndrome in Pregnancy
Obstetric Antiphospholipid Antibody Syndrome : Contribution of the Evaluation of ADAMTS13 Made at the Diagnosis of Pregnancy on Evaluation the Risk of Pre-eclampsia
Study based on data concerning the first pregnancy treated and followed up after the diagnosis of oAPS in the NOH-APS cohort, according to clinical results already published; and on a thematic library collected and preserved at…
- Trial name
- NOH-ADAMTS (NCT04319341)
- Testing
- To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS
- Where
- France
- Volunteers
- 513 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT05859997
- Testing
- BRL-301
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bioray Laboratories